Pharmaceutical Industry

News of Note

Concerta: Brand vs Generic

Topics: Child Psychiatry | News of Note | Pharmaceutical Industry | Psychopharmacology

In November 2016, the FDA announced that it was requiring two companies to withdraw their generic versions of Concerta (OROS methylphenidate) because of efficacy concerns. Such actions are quite unusual, and when they occur, they tend to shake doctors’ confidence in the generic drug system—which branded drug companies are often eager to encourage. B

Read More

Managing Pain: A Cognitive Behavioral Therapist’s Approach [Free Article]